These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 14523789)

  • 1. Oxaliplatin-safety profile: neurotoxicity.
    Grothey A
    Semin Oncol; 2003 Aug; 30(4 Suppl 15):5-13. PubMed ID: 14523789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical management of oxaliplatin-associated neurotoxicity.
    Grothey A
    Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S38-46. PubMed ID: 15871765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral Calcium Ameliorating Oxaliplatin-Induced Peripheral Neuropathy.
    Saif MW
    J Appl Res; 2004 Jan; 4(4):576-582. PubMed ID: 19816592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.
    Lersch C; Schmelz R; Eckel F; Erdmann J; Mayr M; Schulte-Frohlinde E; Quasthoff S; Grosskreutz J; Adelsberger H
    Clin Colorectal Cancer; 2002 May; 2(1):54-8. PubMed ID: 12453338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study].
    Eckel F; Schmelz R; Adelsberger H; Erdmann J; Quasthoff S; Lersch C
    Dtsch Med Wochenschr; 2002 Jan; 127(3):78-82. PubMed ID: 11797144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance).
    Loprinzi CL; Qin R; Dakhil SR; Fehrenbacher L; Flynn KA; Atherton P; Seisler D; Qamar R; Lewis GC; Grothey A
    J Clin Oncol; 2014 Apr; 32(10):997-1005. PubMed ID: 24297951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer.
    Choi J; Kong K; Mozaffar T; Holcombe RF
    Anticancer Drugs; 2006 Jan; 17(1):103-5. PubMed ID: 16317297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin-associated neuropathy: a review.
    Cersosimo RJ
    Ann Pharmacother; 2005 Jan; 39(1):128-35. PubMed ID: 15590869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study.
    Kokotis P; Schmelz M; Kostouros E; Karandreas N; Dimopoulos MA
    Clin Colorectal Cancer; 2016 Sep; 15(3):e133-40. PubMed ID: 27038553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis.
    Wen F; Zhou Y; Wang W; Hu QC; Liu YT; Zhang PF; Du ZD; Dai J; Li Q
    Ann Oncol; 2013 Jan; 24(1):171-8. PubMed ID: 22898039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of chemotherapy-induced peripheral sensory neuropathy, focusing on oxaliplatin.
    Gent P; Massey K
    Int J Palliat Nurs; 2001 Jul; 7(7):354-9. PubMed ID: 11951404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxaliplatin-related neurotoxicity: how and why?
    Pasetto LM; D'Andrea MR; Rossi E; Monfardini S
    Crit Rev Oncol Hematol; 2006 Aug; 59(2):159-68. PubMed ID: 16806962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions].
    Muto O; Ando H; Ono T; Itagaki H; Kobayashi Y; Onuki M; Akashi T; Tanaka Y; Hanaoka T
    Gan To Kagaku Ryoho; 2007 Apr; 34(4):579-81. PubMed ID: 17431344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of calcium/ magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients.
    Kurniali PC; Luo LG; Weitberg AB
    Oncology (Williston Park); 2010 Mar; 24(3):289-92. PubMed ID: 20394142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
    Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
    Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Survey of oxaliplatin-associated peripheral sensory neuropathy using an interview-based questionnaire in patients with advanced colorectal cancer].
    Satomi M; Kono T; Mamiya N; Chisato N; Ebisawa Y; Sugawara M; Saito T; Matsubara K; Kasai S
    Gan To Kagaku Ryoho; 2009 Aug; 36(8):1321-5. PubMed ID: 19692771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
    Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
    Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and safety profile of oxaliplatin.
    Extra JM; Marty M; Brienza S; Misset JL
    Semin Oncol; 1998 Apr; 25(2 Suppl 5):13-22. PubMed ID: 9609104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin in practice.
    Misset JL
    Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):4-7. PubMed ID: 9647612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.